108 related articles for article (PubMed ID: 1651681)
1. [Antitumor agents targeting mammalian topoisomerases].
Nakano H
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1550-5. PubMed ID: 1651681
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
3. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
[TBL] [Abstract][Full Text] [Related]
6. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Beck WT; Danks MK
Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
[TBL] [Abstract][Full Text] [Related]
8. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
[TBL] [Abstract][Full Text] [Related]
9. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
10. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
Wassermann K; Markovits J; Jaxel C; Capranico G; Kohn KW; Pommier Y
Mol Pharmacol; 1990 Jul; 38(1):38-45. PubMed ID: 2164630
[TBL] [Abstract][Full Text] [Related]
11. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
[TBL] [Abstract][Full Text] [Related]
13. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus.
Yamashita Y; Kawada S; Fujii N; Nakano H
Biochemistry; 1991 Jun; 30(24):5838-45. PubMed ID: 1646001
[TBL] [Abstract][Full Text] [Related]
14. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity.
Yamashita Y; Ashizawa T; Morimoto M; Hosomi J; Nakano H
Cancer Res; 1992 May; 52(10):2818-22. PubMed ID: 1316228
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
16. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.
Rowe TC; Chen GL; Hsiang YH; Liu LF
Cancer Res; 1986 Apr; 46(4 Pt 2):2021-6. PubMed ID: 3004716
[TBL] [Abstract][Full Text] [Related]
17. [DNA topoisomerase inhibitor].
Hino M; Niitani H
Nihon Rinsho; 1993 Dec; 51(12):3291-300. PubMed ID: 8283648
[TBL] [Abstract][Full Text] [Related]
18. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
19. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
20. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
de Jong S; Zijlstra JG; de Vries EG; Mulder NH
Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]